Who We Are

At Syndax, we are advancing the next generation of targeted treatments to realize a future in which people with cancer live longer and better than ever before.

We are a commercial stage oncology innovator seeking to develop first-in-class therapies in areas of significant unmet need such as acute leukemia and chronic graft-versus-host disease. Our team is committed to adhering to scientific excellence and dedicated to serving the patient community by delivering therapeutics that provide meaningful and differentiated clinical results and address urgent unmet need.

Treatment Pipeline

View Pipeline
drop

Revumenib

Revumenib is a potent, selective, small molecule inhibitor of the menin-KMT2A interaction being developed for the treatment of KMT2A-rearranged acute leukemias, including acute lymphoid leukemia and acute myeloid leukemia (AML), and NPM1-mutated AML.

Explore More

Axatilimab

In addition to its first indication, Syndax aims to investigate axatilimab in earlier lines of therapy in combination with standard of care agents and in potential indications such as idiopathic pulmonary fibrosis, where a Phase 2 clinical trial is ongoing.

Explore more
background
Explore More

Syndax is proud to announce that the U.S. Food and Drug Administration has approved Niktimvo™ (axatilimab-csfr)!

Learn more
Please see Full Prescribing Information here.
;